ondansetron has been researched along with Gastroenteritis in 79 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Gastroenteritis: INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the cost-effectiveness of adding oral ondansetron to care as usual (CAU) for children with acute gastroenteritis presenting to out-of-hours primary care (OOH-PC)." | 9.41 | Cost-effectiveness of oral ondansetron for children with acute gastroenteritis in primary care: a randomised controlled trial. ( Berger, MY; Bonvanie, IJ; Holtman, GA; Kollen, BJ; Vermeulen, KM; Weghorst, AA; Wolters, PI, 2021) |
| " In secondary care, ondansetron was found to be effective at reducing vomiting." | 9.41 | Oral ondansetron for paediatric gastroenteritis in primary care: a randomised controlled trial. ( Berger, MY; Bonvanie, IJ; Fickweiler, F; Holtman, GA; Kollen, BJ; Russchen, HA; Verkade, HJ; Weghorst, AA, 2021) |
| " In September 2019 the study began recruiting children aged 6 months to 18 years with a minimum of three episodes of vomiting in the 24 h preceding enrollment, <72 h of gastroenteritis symptoms and who were administered a dose of ondansetron during their ED visit." | 9.34 | Multi-dose Oral Ondansetron for Pediatric Gastroenteritis: study Protocol for the multi-DOSE oral ondansetron for pediatric Acute GastroEnteritis (DOSE-AGE) pragmatic randomized controlled trial. ( Beer, D; Dixon, A; Finkelstein, Y; Freedman, SB; Gouin, S; Heath, A; Hopkin, G; Joubert, G; Klassen, TP; McCabe, C; Pechlivanoglou, P; Plint, AC; Williamson-Urquhart, S, 2020) |
| "The DOSE-AGE study is a phase III, 6-center, placebo-controlled, double-blind, parallel design randomized controlled trial designed to determine whether participants who are prescribed multiple doses of oral ondansetron to administer, as needed, following their ED visit have a lower incidence of experiencing moderate-to-severe gastroenteritis, as measured by the Modified Vesikari Scale score, compared with a placebo." | 9.34 | A pragmatic randomized controlled trial of multi-dose oral ondansetron for pediatric gastroenteritis (the DOSE-AGE study): statistical analysis plan. ( Beer, D; Dixon, A; Freedman, SB; Gouin, S; Heath, A; Hopkin, G; Joubert, G; Klassen, TP; McCabe, C; Offringa, M; Pechlivanoglou, P; Plint, AC; Rios, JD; Williamson-Urquhart, S, 2020) |
| "In hospitalized children having gastro-enteritis associated with emesis, ondansetron is effective in the cessation of episodes of vomiting and in lowering the rates of IV rehydration, without reducing the duration of diarrhea and hospital stay." | 9.30 | Single-dose Intravenous Ondansetron in Children with Gastroenteritis: A Randomized Controlled Trial. ( Chanh, TQ; My, PT; Rang, NN; Tien, TTM, 2019) |
| "To determine whether an experimental long-acting bimodal release ondansetron tablet decreases gastroenteritis-related vomiting and eliminates the need for intravenous therapy for 24 hours after administration." | 9.30 | Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial. ( Avarello, J; Fathi, R; Hahn, B; House, SL; Kalfus, IN; Lovato, LM; Meltzer, AC; Miller, JB; Plasse, TF; Raday, G; Silverman, RA; Yan, EC, 2019) |
| "To compare the efficacy and safety of ondansetron versus less expensive metoclopramide in the treatment of children with persistent vomiting with acute gastroenteritis." | 9.15 | Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis. ( Abdulateef, H; Al-Ansari, K; Alomary, S; Alshawagfa, M; Kamal, K, 2011) |
| "To compare the efficacy of ondansetron and domperidone for the symptomatic treatment of vomiting in children with AG who have failed ORT." | 9.15 | Oral ondansetron versus domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial. ( Arrighini, A; Bertolani, P; Biban, P; Bonati, M; Clavenna, A; Da Dalt, L; Di Pietro, P; Guala, A; Maestro, A; Mannelli, F; Marchetti, F; Messi, G; Pazzaglia, A; Perri, F; Reale, A; Renna, S; Ronfani, L; Rovere, F; Tondelli, MT; Urbino, AF; Valletta, E; Vitale, A; Zangardi, T; Zanon, D, 2011) |
| " Data were collected on 105 children with dehydration due to gastroenteritis who received an ondansetron oral disintegrating formulation." | 9.14 | Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study. ( Finkelstein, Y; Freedman, SB; Nava-Ocampo, AA; Powell, EC, 2010) |
| "To investigate potential beneficial effects of ondansetron in treating vomiting during acute gastroenteritis." | 9.14 | Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study. ( Sertdemir, Y; Yildizdas, RD; Yilmaz, HL, 2010) |
| "We hypothesize that ondansetron will facilitate oral rehydration therapy in children with acute gastritis or acute gastroenteritis and mild to moderate dehydration who fail initial oral rehydration therapy." | 9.13 | The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial. ( Hepps, TS; McQuillen, KK; Roslund, G, 2008) |
| "In children with gastroenteritis and dehydration, a single dose of oral ondansetron reduces vomiting and facilitates oral rehydration and may thus be well suited for use in the emergency department." | 9.12 | Oral ondansetron for gastroenteritis in a pediatric emergency department. ( Adler, M; Freedman, SB; Powell, EC; Seshadri, R, 2006) |
| "Ondansetron was effective in reducing the emesis from gastroenteritis during the ED phase of oral rehydration and in lowering the rates of intravenous fluid administration and hospital admission." | 9.10 | A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. ( Kozinetz, CA; Moro-Sutherland, D; Ramsook, C; Sahagun-Carreon, I, 2002) |
| "Intravenous ondansetron decreases vomiting in children with gastroenteritis." | 9.10 | Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial. ( Fleisher, GR; Reeves, JJ; Shannon, MW, 2002) |
| "048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (P = 0." | 9.08 | Antiemetic activity of ondansetron in acute gastroenteritis. ( Cubeddu, LX; Gonzalez, V; Guariguata, J; Miller, IA; Paska, W; Seijas, J; Talmaciu, I; Trujillo, LM, 1997) |
| "This review aimed to meta-analyze evidence of efficacy and safety of one single dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis." | 9.05 | Single-dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis-an updated systematic review and meta-analysis. ( Biagi, C; Filice, E; Fugetto, F; Gori, D; Lanari, M; Pierantoni, L, 2020) |
| " ondansetron is an effective antiemetic in children with gastroenteritis, but data from low- and middle-income countries are sparse." | 9.05 | Effect of ondansetron on vomiting associated with acute gastroenteritis in a developing country: a meta-analysis. ( Wu, HL; Zhan, X, 2020) |
| "To systematically update evidence on the effects of ondansetron (5-HT3 serotonin antagonist) for vomiting in children with acute gastroenteritis." | 8.93 | Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis. ( Kołodziej, M; Szajewska, H; Tomasik, E; Ziółkowska, E, 2016) |
| "To investigate potential beneficial effects of ondansetron, compared with placebo or no intervention, in treating vomiting during acute gastroenteritis in children." | 8.84 | Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children. ( Dylag, M; Gieruszczak-Białek, D; Szajewska, H, 2007) |
| "Among preschool-aged children with gastroenteritis seeking ED care, oral ondansetron administration was associated with a reduction in index ED visit intravenous fluid administration; it was not associated with intravenous fluids administered within 72 hours, hospitalization, or vomiting and diarrhea in the 24 hours following discharge." | 8.12 | Oral Ondansetron Administration in Children Seeking Emergency Department Care for Acute Gastroenteritis: A Patient-Level Propensity-Matched Analysis. ( Bhatt, SR; Casper, TC; Farion, KJ; Freedman, SB; Gouin, S; Hurley, K; Levine, AC; Mahajan, P; O'Connell, KJ; Olsen, CS; Poonai, N; Powell, EC; Rogers, AJ; Roskind, CG; Sapien, RE; Schnadower, D; Schuh, S; Tarr, PI; Vance, C, 2022) |
| "At several out-of-hours services primary care, a single dose of ondansetron was compared with standard care (oral rehydration solution (ORS)) in young children with gastroenteritis and persistent vomiting." | 8.12 | [No place for ondansetron in young children with gastroenteritis and persistent vomiting]. ( Wichers, IM, 2022) |
| "In paediatric patients with acute gastroenteritis (AGE), ondansetron use decreases the need for intravenous fluids, reduces hospitalisations and shortens illness duration." | 8.12 | Improving ondansetron use and oral rehydration instructions for pediatric acute gastroenteritis. ( Heyman, M; Patel, PV; Rosenbluth, G; Verstraete, S; Wallach, T, 2022) |
| "The objective of this study was to determine if providing ondansetron prescription to children with acute gastroenteritis seen in the emergency department (ED) is associated with reduced unscheduled ED revisits." | 8.02 | Impact of Ondansetron Prescription on Return Emergency Department Visits Among Children with Acute Gastroenteritis. ( Fleegler, EW; McLaren, SH; Yim, RB, 2021) |
| "We determine whether an ondansetron prescription for pediatric patients with vomiting or gastroenteritis is associated with decreased return visits to the emergency department (ED), and whether alternate diagnoses are more frequent on return visits in patients prescribed ondansetron." | 7.96 | Ondansetron Prescription Is Associated With Reduced Return Visits to the Pediatric Emergency Department for Children With Gastroenteritis. ( Benary, D; Higley, R; Lowe, D; Lozano, JM, 2020) |
| "We have sought to determine the effect of a standardized dose of intravenous ondansetron on the QTc duration of children under 14years of age treated for gastroenteritis-associated vomiting in a pediatric ED." | 7.88 | Effect of intravenous ondansetron on QTc interval in children with gastroenteritis. ( Alansari, K; Hoffman, RJ, 2018) |
| "This is a single-center prospective study enrolling children aged 3-8 years with gastroenteritis treated for persistent vomiting; patients received single dose of flavored intravenous ondansetron orally." | 7.83 | Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting in Children. ( Al Ansari, K; Ibrahim, K, 2016) |
| "Ondansetron is often used in the emergency department (ED) to promote oral rehydration in children with acute gastroenteritis (AGE), yet medication solutions administered orally may be poorly tolerated in this population." | 7.83 | Ondansetron Oral Dissolve Tab vs. Oral Solution in Children Presenting to the Emergency Department with Gastroenteritis. ( Chaulk, D; Johnson, DW; Kwong, S; Morrison, EL; Thompson, GC; Wobma, H, 2016) |
| "Ondansetron hydrochloride use in children with gastroenteritis is increasing rapidly; however, little is known about its impact on outcomes." | 7.80 | Impact of increasing ondansetron use on clinical outcomes in children with gastroenteritis. ( Aronson, PL; Florin, TA; Freedman, SB; Hall, M; Kharbanda, AB; Macias, CG; Mistry, RD; Neuman, MI; Shah, SS, 2014) |
| "This study describes the introduction of Ondansetron to an established waiting room Oral Rehydration Therapy (ORT) for Emergency Department (ED) children with acute gastroenteritis, and evaluates its impact on intravenous fluid administration and admissions." | 7.79 | The addition of ondansetron to a oral rehydration protocol for children with acute gastroenteritis. ( Crowley, E; Martin, C; Mullarkey, C, 2013) |
| "Emergency department use of ondansetron in children with gastroenteritis is increasing; however, its effect on clinical outcomes is unknown." | 7.78 | Time-series analysis of ondansetron use in pediatric gastroenteritis. ( Chan, KJ; Cho, D; Freedman, SB; Rumantir, M; Tung, C, 2012) |
| "A cost analysis evaluated oral ondansetron administration to children presenting to emergency departments with vomiting and dehydration secondary to gastroenteritis from a societal and health care payer's perspective in both the US and Canada." | 7.76 | Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis. ( Chan, KJ; Freedman, SB; Steiner, MJ, 2010) |
| " Ondansetron has been well tolerated when used to control nausea and vomiting in patients receiving chemotherapy." | 7.73 | Ondansetron for acute gastroenteritis in children. ( Goldman, RD; Mehta, S, 2006) |
| "Domperidone was not effective for the symptomatic treatment of vomiting during acute gastroenteritis." | 6.82 | Oral Ondansetron versus Domperidone for Acute Gastroenteritis in Pediatric Emergency Departments: Multicenter Double Blind Randomized Controlled Trial. ( Arrighini, A; Barbi, E; Bertolani, P; Biban, P; Bonati, M; Clavenna, A; Da Dalt, L; Guala, A; Maestro, A; Marchetti, F; Mazzoni, E; Pazzaglia, A; Perri, PF; Reale, A; Renna, S; Ronfani, L; Rovere, F; Urbino, AF; Valletta, E; Vitale, A; Zangardi, T; Zanon, D, 2016) |
| "Ondansetron use has increased significantly; however, 'real-world' studies of effectiveness have documented less impressive clinical impacts." | 6.52 | Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries. ( Finkelstein, Y; Freedman, SB; Schnadower, D, 2015) |
| " In secondary care, ondansetron was found to be effective at reducing vomiting." | 5.41 | Oral ondansetron for paediatric gastroenteritis in primary care: a randomised controlled trial. ( Berger, MY; Bonvanie, IJ; Fickweiler, F; Holtman, GA; Kollen, BJ; Russchen, HA; Verkade, HJ; Weghorst, AA, 2021) |
| "To determine the cost-effectiveness of adding oral ondansetron to care as usual (CAU) for children with acute gastroenteritis presenting to out-of-hours primary care (OOH-PC)." | 5.41 | Cost-effectiveness of oral ondansetron for children with acute gastroenteritis in primary care: a randomised controlled trial. ( Berger, MY; Bonvanie, IJ; Holtman, GA; Kollen, BJ; Vermeulen, KM; Weghorst, AA; Wolters, PI, 2021) |
| "The DOSE-AGE study is a phase III, 6-center, placebo-controlled, double-blind, parallel design randomized controlled trial designed to determine whether participants who are prescribed multiple doses of oral ondansetron to administer, as needed, following their ED visit have a lower incidence of experiencing moderate-to-severe gastroenteritis, as measured by the Modified Vesikari Scale score, compared with a placebo." | 5.34 | A pragmatic randomized controlled trial of multi-dose oral ondansetron for pediatric gastroenteritis (the DOSE-AGE study): statistical analysis plan. ( Beer, D; Dixon, A; Freedman, SB; Gouin, S; Heath, A; Hopkin, G; Joubert, G; Klassen, TP; McCabe, C; Offringa, M; Pechlivanoglou, P; Plint, AC; Rios, JD; Williamson-Urquhart, S, 2020) |
| " In September 2019 the study began recruiting children aged 6 months to 18 years with a minimum of three episodes of vomiting in the 24 h preceding enrollment, <72 h of gastroenteritis symptoms and who were administered a dose of ondansetron during their ED visit." | 5.34 | Multi-dose Oral Ondansetron for Pediatric Gastroenteritis: study Protocol for the multi-DOSE oral ondansetron for pediatric Acute GastroEnteritis (DOSE-AGE) pragmatic randomized controlled trial. ( Beer, D; Dixon, A; Finkelstein, Y; Freedman, SB; Gouin, S; Heath, A; Hopkin, G; Joubert, G; Klassen, TP; McCabe, C; Pechlivanoglou, P; Plint, AC; Williamson-Urquhart, S, 2020) |
| "Among children with gastroenteritis-associated vomiting and dehydration, oral ondansetron administration reduced vomiting and intravenous rehydration use." | 5.30 | Oral Ondansetron Administration to Dehydrated Children in Pakistan: A Randomized Clinical Trial. ( Bhutta, ZA; Dawoud, F; Freedman, SB; Siddiqui, E; Soofi, SB; Willan, AR; Williamson-Urquhart, S; Xie, J, 2019) |
| "To determine whether an experimental long-acting bimodal release ondansetron tablet decreases gastroenteritis-related vomiting and eliminates the need for intravenous therapy for 24 hours after administration." | 5.30 | Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial. ( Avarello, J; Fathi, R; Hahn, B; House, SL; Kalfus, IN; Lovato, LM; Meltzer, AC; Miller, JB; Plasse, TF; Raday, G; Silverman, RA; Yan, EC, 2019) |
| "In hospitalized children having gastro-enteritis associated with emesis, ondansetron is effective in the cessation of episodes of vomiting and in lowering the rates of IV rehydration, without reducing the duration of diarrhea and hospital stay." | 5.30 | Single-dose Intravenous Ondansetron in Children with Gastroenteritis: A Randomized Controlled Trial. ( Chanh, TQ; My, PT; Rang, NN; Tien, TTM, 2019) |
| "To compare the efficacy and safety of ondansetron versus less expensive metoclopramide in the treatment of children with persistent vomiting with acute gastroenteritis." | 5.15 | Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis. ( Abdulateef, H; Al-Ansari, K; Alomary, S; Alshawagfa, M; Kamal, K, 2011) |
| "To compare the efficacy of ondansetron and domperidone for the symptomatic treatment of vomiting in children with AG who have failed ORT." | 5.15 | Oral ondansetron versus domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial. ( Arrighini, A; Bertolani, P; Biban, P; Bonati, M; Clavenna, A; Da Dalt, L; Di Pietro, P; Guala, A; Maestro, A; Mannelli, F; Marchetti, F; Messi, G; Pazzaglia, A; Perri, F; Reale, A; Renna, S; Ronfani, L; Rovere, F; Tondelli, MT; Urbino, AF; Valletta, E; Vitale, A; Zangardi, T; Zanon, D, 2011) |
| " Data were collected on 105 children with dehydration due to gastroenteritis who received an ondansetron oral disintegrating formulation." | 5.14 | Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study. ( Finkelstein, Y; Freedman, SB; Nava-Ocampo, AA; Powell, EC, 2010) |
| "To investigate potential beneficial effects of ondansetron in treating vomiting during acute gastroenteritis." | 5.14 | Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study. ( Sertdemir, Y; Yildizdas, RD; Yilmaz, HL, 2010) |
| "We hypothesize that ondansetron will facilitate oral rehydration therapy in children with acute gastritis or acute gastroenteritis and mild to moderate dehydration who fail initial oral rehydration therapy." | 5.13 | The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial. ( Hepps, TS; McQuillen, KK; Roslund, G, 2008) |
| "In children with gastroenteritis and dehydration, a single dose of oral ondansetron reduces vomiting and facilitates oral rehydration and may thus be well suited for use in the emergency department." | 5.12 | Oral ondansetron for gastroenteritis in a pediatric emergency department. ( Adler, M; Freedman, SB; Powell, EC; Seshadri, R, 2006) |
| "Intravenous ondansetron decreases vomiting in children with gastroenteritis." | 5.10 | Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial. ( Fleisher, GR; Reeves, JJ; Shannon, MW, 2002) |
| "Ondansetron was effective in reducing the emesis from gastroenteritis during the ED phase of oral rehydration and in lowering the rates of intravenous fluid administration and hospital admission." | 5.10 | A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. ( Kozinetz, CA; Moro-Sutherland, D; Ramsook, C; Sahagun-Carreon, I, 2002) |
| "048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (P = 0." | 5.08 | Antiemetic activity of ondansetron in acute gastroenteritis. ( Cubeddu, LX; Gonzalez, V; Guariguata, J; Miller, IA; Paska, W; Seijas, J; Talmaciu, I; Trujillo, LM, 1997) |
| "This review aimed to meta-analyze evidence of efficacy and safety of one single dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis." | 5.05 | Single-dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis-an updated systematic review and meta-analysis. ( Biagi, C; Filice, E; Fugetto, F; Gori, D; Lanari, M; Pierantoni, L, 2020) |
| " Ondansetron revealed the largest effect in comparison to placebo for cessation of vomiting (odds ratio = 0." | 5.05 | Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis. ( Acosta-Reyes, J; Florez, ID; Niño-Serna, LF; Veroniki, AA, 2020) |
| " ondansetron is an effective antiemetic in children with gastroenteritis, but data from low- and middle-income countries are sparse." | 5.05 | Effect of ondansetron on vomiting associated with acute gastroenteritis in a developing country: a meta-analysis. ( Wu, HL; Zhan, X, 2020) |
| "Well-designed investigations suggest that antagonists of the type 3 serotonin receptor, most frequently oral ondansetron, reduce the rate of vomiting, improve the tolerance of oral rehydration, and reduce the need for intravenous rehydration." | 4.98 | Clinical Practice: Nausea and vomiting in acute gastroenteritis: physiopathology and management. ( Agostoni, C; Bianchetti, MG; Canziani, BC; Fossali, EF; Lava, SAG; Milani, GP; Uestuener, P, 2018) |
| "To systematically update evidence on the effects of ondansetron (5-HT3 serotonin antagonist) for vomiting in children with acute gastroenteritis." | 4.93 | Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis. ( Kołodziej, M; Szajewska, H; Tomasik, E; Ziółkowska, E, 2016) |
| "Oral ondansetron increased the proportion of patients who had ceased vomiting and reduced the number needing intravenous rehydration and immediate hospital admission." | 4.87 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Carter, B; Fedorowicz, Z; Jagannath, VA, 2011) |
| "The small number of included trials provided some limited evidence favouring the use of ondansetron and metoclopramide over placebo to reduce the number of episodes of vomiting due to gastroenteritis in children." | 4.85 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Al-Hashimi, H; Alhashimi, D; Fedorowicz, Z, 2009) |
| "To investigate potential beneficial effects of ondansetron, compared with placebo or no intervention, in treating vomiting during acute gastroenteritis in children." | 4.84 | Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children. ( Dylag, M; Gieruszczak-Białek, D; Szajewska, H, 2007) |
| "The small number of included trials provided some, albeit weak and unreliable, evidence which appeared to favor the use of ondansetron and metoclopramide over placebo to reduce the number of episodes of vomiting due to gastroenteritis in children." | 4.83 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Alhashimi, D; Alhashimi, H; Fedorowicz, Z, 2006) |
| "The small number of included trials provided some, albeit weak and unreliable, evidence which appeared to favor the use of ondansetron and metoclopramide over placebo to reduce the number of episodes of vomiting due to gastroenteritis in children." | 4.83 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Alhashimi, D; Alhashimi, H; Fedorowicz, Z, 2006) |
| "Among preschool-aged children with gastroenteritis seeking ED care, oral ondansetron administration was associated with a reduction in index ED visit intravenous fluid administration; it was not associated with intravenous fluids administered within 72 hours, hospitalization, or vomiting and diarrhea in the 24 hours following discharge." | 4.12 | Oral Ondansetron Administration in Children Seeking Emergency Department Care for Acute Gastroenteritis: A Patient-Level Propensity-Matched Analysis. ( Bhatt, SR; Casper, TC; Farion, KJ; Freedman, SB; Gouin, S; Hurley, K; Levine, AC; Mahajan, P; O'Connell, KJ; Olsen, CS; Poonai, N; Powell, EC; Rogers, AJ; Roskind, CG; Sapien, RE; Schnadower, D; Schuh, S; Tarr, PI; Vance, C, 2022) |
| "At several out-of-hours services primary care, a single dose of ondansetron was compared with standard care (oral rehydration solution (ORS)) in young children with gastroenteritis and persistent vomiting." | 4.12 | [No place for ondansetron in young children with gastroenteritis and persistent vomiting]. ( Wichers, IM, 2022) |
| "Sex, age, preceding health care visit, distance between home and hospital, country (US vs Canada), frequency and duration of vomiting and diarrhea, presence of fever, Clinical Dehydration Scale score, oral ondansetron followed by oral rehydration therapy, and infectious agent." | 4.02 | Variables Associated With Intravenous Rehydration and Hospitalization in Children With Acute Gastroenteritis: A Secondary Analysis of 2 Randomized Clinical Trials. ( Bhatt, S; Casper, TC; Farion, KJ; Freedman, SB; Gouin, S; Hurley, KF; Levine, AC; Mahajan, P; O'Connell, KJ; Olsen, CS; Poonai, N; Powell, EC; Rogers, AJ; Roskind, CG; Sapien, RE; Schnadower, D; Schuh, S; Tarr, PI; Vance, C, 2021) |
| "We determine whether an ondansetron prescription for pediatric patients with vomiting or gastroenteritis is associated with decreased return visits to the emergency department (ED), and whether alternate diagnoses are more frequent on return visits in patients prescribed ondansetron." | 3.96 | Ondansetron Prescription Is Associated With Reduced Return Visits to the Pediatric Emergency Department for Children With Gastroenteritis. ( Benary, D; Higley, R; Lowe, D; Lozano, JM, 2020) |
| "Ondansetron has been shown to decrease admission rate and the need for intravenous fluids among pediatric emergency department (ED) patients with acute gastroenteritis, but there is limited evidence regarding its use after ED discharge." | 3.96 | Ondansetron Prescription for Home Use in a Pediatric Emergency Department. ( Furnival, RA; Gray, JM; Hendrickson, MA; Lunos, SA; Maewal, JD, 2020) |
| "We have sought to determine the effect of a standardized dose of intravenous ondansetron on the QTc duration of children under 14years of age treated for gastroenteritis-associated vomiting in a pediatric ED." | 3.88 | Effect of intravenous ondansetron on QTc interval in children with gastroenteritis. ( Alansari, K; Hoffman, RJ, 2018) |
| "Guidelines recommend oral rehydration therapy (ORT) and avoidance of laboratory tests and intravenous fluids for mild to moderate dehydration in children with gastroenteritis; oral ondansetron has been shown to be an effective adjunct." | 3.88 | The Use of a Triage-Based Protocol for Oral Rehydration in a Pediatric Emergency Department. ( Gaillard, PR; Hendrickson, MA; Kharbanda, AB; Wey, AR; Zaremba, J, 2018) |
| "This is a single-center prospective study enrolling children aged 3-8 years with gastroenteritis treated for persistent vomiting; patients received single dose of flavored intravenous ondansetron orally." | 3.83 | Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting in Children. ( Al Ansari, K; Ibrahim, K, 2016) |
| "Ondansetron is commonly used to treat vomiting in gastroenteritis, but has a United States Food and Drug Administration black box warning for risk of Q wave to T wave time interval (QT) prolongation." | 3.83 | Fatal Cardiac Arrest in 2 Children: Possible Role of Ondansetron. ( Boucher, J; Brenner, SM, 2016) |
| "Ondansetron is often used in the emergency department (ED) to promote oral rehydration in children with acute gastroenteritis (AGE), yet medication solutions administered orally may be poorly tolerated in this population." | 3.83 | Ondansetron Oral Dissolve Tab vs. Oral Solution in Children Presenting to the Emergency Department with Gastroenteritis. ( Chaulk, D; Johnson, DW; Kwong, S; Morrison, EL; Thompson, GC; Wobma, H, 2016) |
| "This study describes the introduction of Ondansetron to an established waiting room Oral Rehydration Therapy (ORT) for Emergency Department (ED) children with acute gastroenteritis, and evaluates its impact on intravenous fluid administration and admissions." | 3.79 | The addition of ondansetron to a oral rehydration protocol for children with acute gastroenteritis. ( Crowley, E; Martin, C; Mullarkey, C, 2013) |
| "Emergency department use of ondansetron in children with gastroenteritis is increasing; however, its effect on clinical outcomes is unknown." | 3.78 | Time-series analysis of ondansetron use in pediatric gastroenteritis. ( Chan, KJ; Cho, D; Freedman, SB; Rumantir, M; Tung, C, 2012) |
| "We evaluate the effect of ondansetron use in cases of suspected gastroenteritis on the proportion of hospital admissions and return visits and assess whether children who receive ondansetron on their initial visit to the pediatric emergency department (ED) for suspected gastroenteritis return with an alternative diagnosis more frequently than those who did not receive ondansetron." | 3.76 | Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses? ( Hirsh, DA; Massey, R; Schweickert, A; Simon, HK; Sturm, JJ, 2010) |
| "A cost analysis evaluated oral ondansetron administration to children presenting to emergency departments with vomiting and dehydration secondary to gastroenteritis from a societal and health care payer's perspective in both the US and Canada." | 3.76 | Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis. ( Chan, KJ; Freedman, SB; Steiner, MJ, 2010) |
| " Ondansetron has been well tolerated when used to control nausea and vomiting in patients receiving chemotherapy." | 3.73 | Ondansetron for acute gastroenteritis in children. ( Goldman, RD; Mehta, S, 2006) |
| "Domperidone was not effective for the symptomatic treatment of vomiting during acute gastroenteritis." | 2.82 | Oral Ondansetron versus Domperidone for Acute Gastroenteritis in Pediatric Emergency Departments: Multicenter Double Blind Randomized Controlled Trial. ( Arrighini, A; Barbi, E; Bertolani, P; Biban, P; Bonati, M; Clavenna, A; Da Dalt, L; Guala, A; Maestro, A; Marchetti, F; Mazzoni, E; Pazzaglia, A; Perri, PF; Reale, A; Renna, S; Ronfani, L; Rovere, F; Urbino, AF; Valletta, E; Vitale, A; Zangardi, T; Zanon, D, 2016) |
| "Acute gastroenteritis is defined as a diarrheal disease of rapid onset, with or without nausea, vomiting, fever, or abdominal pain." | 2.61 | Gastroenteritis in Children. ( Brown, E; Hartman, S; Loomis, E; Russell, HA, 2019) |
| "Ondansetron use has increased significantly; however, 'real-world' studies of effectiveness have documented less impressive clinical impacts." | 2.52 | Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries. ( Finkelstein, Y; Freedman, SB; Schnadower, D, 2015) |
| " Although probiotics appear to be an effective option for the treatment of AGE amongst hospitalized children, outpatient data is lacking and more studies are urgently needed to determine the optimal organism, dosing and duration of treatment." | 2.49 | Treatment of acute gastroenteritis in children: an overview of systematic reviews of interventions commonly used in developed countries. ( Ali, S; Freedman, SB; Gouin, S; Hartling, L; Oleszczuk, M, 2013) |
| "Ondansetron has proven to be a safe and effective adjunct in children with vomiting." | 1.46 | Clinical Pathway Produces Sustained Improvement in Acute Gastroenteritis Care. ( Brown, JC; Klein, EJ; Rutman, L, 2017) |
| "Racecadotril was more frequently used in France, and ondansetron was more frequently used in Switzerland." | 1.40 | Pediatric gastroenteritis in the emergency department: practice evaluation in Belgium, France, The Netherlands and Switzerland. ( Angoulvant, F; Gajdos, V; Julliand, S; Llor, J; Lorrot, M; Oostenbrink, R; Pelc, R; Redant, S, 2014) |
| "Acute gastroenteritis is a very common emergency department (ED) diagnosis accounting for greater than 1." | 1.37 | The treatment of pediatric gastroenteritis: a comparative analysis of pediatric emergency physicians' practice patterns. ( Bohn, V; Boutis, K; Freedman, SB; Johnson, DW; Powell, EC; Sivabalasundaram, V, 2011) |
| "For moderate dehydration, eight CPGs advocated nasogastric (NG) rehydration in preference to intravenous (IV) rehydration." | 1.35 | Emergency department management of gastro-enteritis in Australia and New Zealand. ( Babl, FE; Borland, M; Schutz, J; Sheriff, N, 2008) |
| "Ondansetron was used in a minor proportion of antiemetic prescriptions (Germany, Canada, Spain, and Italy, 0%; United States, 3%; United Kingdom, 6%)." | 1.35 | Antiemetic medications in children with presumed infectious gastroenteritis--pharmacoepidemiology in Europe and Northern America. ( Carius, R; Kiess, W; Kostev, K; Pfeil, N; Schröder, H; Uhlig, HH; Uhlig, U, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.27) | 18.2507 |
| 2000's | 16 (20.25) | 29.6817 |
| 2010's | 40 (50.63) | 24.3611 |
| 2020's | 22 (27.85) | 2.80 |
| Authors | Studies |
|---|---|
| Gill, PJ | 1 |
| Thomas, E | 1 |
| Van den Bruel, A | 1 |
| Yang, H | 1 |
| Jeon, W | 1 |
| Ko, Y | 1 |
| Jeong, S | 1 |
| Lee, J | 1 |
| Lipshaw, MJ | 1 |
| Patel, PV | 1 |
| Wallach, T | 1 |
| Rosenbluth, G | 1 |
| Heyman, M | 1 |
| Verstraete, S | 1 |
| Dickerson-Young, T | 1 |
| Uspal, NG | 1 |
| Prince, WB | 1 |
| Qu, P | 1 |
| Klein, EJ | 2 |
| Wichers, IM | 1 |
| McLaren, SH | 1 |
| Yim, RB | 1 |
| Fleegler, EW | 1 |
| Freedman, SB | 15 |
| Soofi, SB | 1 |
| Willan, AR | 1 |
| Williamson-Urquhart, S | 3 |
| Siddiqui, E | 1 |
| Xie, J | 1 |
| Dawoud, F | 1 |
| Bhutta, ZA | 1 |
| Silverman, RA | 1 |
| House, SL | 1 |
| Meltzer, AC | 1 |
| Hahn, B | 2 |
| Lovato, LM | 1 |
| Avarello, J | 2 |
| Miller, JB | 1 |
| Kalfus, IN | 1 |
| Fathi, R | 2 |
| Raday, G | 1 |
| Plasse, TF | 1 |
| Yan, EC | 1 |
| Chandrasekar, S | 1 |
| John, J | 1 |
| Nguyen, RN | 1 |
| Niño-Serna, LF | 1 |
| Acosta-Reyes, J | 1 |
| Veroniki, AA | 1 |
| Florez, ID | 1 |
| Miller, J | 1 |
| House, S | 1 |
| Lovato, L | 1 |
| Meltzer, A | 1 |
| Plasse, T | 1 |
| Kalfus, I | 1 |
| Silverman, R | 1 |
| Fugetto, F | 1 |
| Filice, E | 1 |
| Biagi, C | 1 |
| Pierantoni, L | 1 |
| Gori, D | 1 |
| Lanari, M | 1 |
| Heath, A | 2 |
| Pechlivanoglou, P | 2 |
| Hopkin, G | 2 |
| Gouin, S | 5 |
| Plint, AC | 2 |
| Dixon, A | 2 |
| Beer, D | 2 |
| Joubert, G | 2 |
| McCabe, C | 2 |
| Finkelstein, Y | 3 |
| Klassen, TP | 2 |
| Benary, D | 1 |
| Lozano, JM | 1 |
| Higley, R | 1 |
| Lowe, D | 1 |
| Wu, HL | 1 |
| Zhan, X | 1 |
| Funk, A | 1 |
| Schnadower, D | 4 |
| Rios, JD | 1 |
| Offringa, M | 1 |
| Lloyd-Martin, E | 1 |
| Poonai, N | 2 |
| Powell, EC | 5 |
| Casper, TC | 2 |
| Roskind, CG | 2 |
| Olsen, CS | 2 |
| Tarr, PI | 2 |
| Mahajan, P | 2 |
| Rogers, AJ | 2 |
| Schuh, S | 2 |
| Hurley, KF | 1 |
| Vance, C | 2 |
| Farion, KJ | 2 |
| Sapien, RE | 2 |
| O'Connell, KJ | 2 |
| Levine, AC | 2 |
| Bhatt, S | 1 |
| Baker, AH | 1 |
| Eisenberg, M | 1 |
| Weghorst, AA | 2 |
| Holtman, GA | 2 |
| Bonvanie, IJ | 2 |
| Wolters, PI | 1 |
| Kollen, BJ | 2 |
| Vermeulen, KM | 1 |
| Berger, MY | 2 |
| Bhatt, SR | 1 |
| Hurley, K | 1 |
| Russchen, HA | 1 |
| Fickweiler, F | 1 |
| Verkade, HJ | 1 |
| Rutman, L | 1 |
| Brown, JC | 1 |
| Canziani, BC | 1 |
| Uestuener, P | 1 |
| Fossali, EF | 1 |
| Lava, SAG | 1 |
| Bianchetti, MG | 1 |
| Agostoni, C | 1 |
| Milani, GP | 1 |
| Hoffman, RJ | 1 |
| Alansari, K | 1 |
| Gray, JM | 1 |
| Maewal, JD | 1 |
| Lunos, SA | 1 |
| Furnival, RA | 1 |
| Hendrickson, MA | 2 |
| Bergemalm, J | 1 |
| Ludvigsson, JF | 1 |
| Hartman, S | 1 |
| Brown, E | 1 |
| Loomis, E | 1 |
| Russell, HA | 1 |
| Rang, NN | 1 |
| Chanh, TQ | 1 |
| My, PT | 1 |
| Tien, TTM | 1 |
| Ali, S | 1 |
| Oleszczuk, M | 1 |
| Hartling, L | 1 |
| DeGroot, JM | 1 |
| Parkin, PC | 1 |
| Mullarkey, C | 1 |
| Crowley, E | 1 |
| Martin, C | 1 |
| Keren, R | 1 |
| Hall, M | 1 |
| Shah, SS | 1 |
| Kharbanda, AB | 2 |
| Aronson, PL | 1 |
| Florin, TA | 1 |
| Mistry, RD | 1 |
| Macias, CG | 1 |
| Neuman, MI | 1 |
| Pelc, R | 1 |
| Redant, S | 1 |
| Julliand, S | 1 |
| Llor, J | 1 |
| Lorrot, M | 1 |
| Oostenbrink, R | 1 |
| Gajdos, V | 1 |
| Angoulvant, F | 1 |
| Lalani, N | 1 |
| Gaco, D | 1 |
| Ibrahim, K | 1 |
| Al Ansari, K | 1 |
| Tomasik, E | 1 |
| Ziółkowska, E | 1 |
| Kołodziej, M | 1 |
| Szajewska, H | 2 |
| Thompson, GC | 1 |
| Morrison, EL | 1 |
| Chaulk, D | 1 |
| Wobma, H | 1 |
| Kwong, S | 1 |
| Johnson, DW | 2 |
| Marzuillo, P | 1 |
| Vecchione, E | 1 |
| D'Anna, C | 1 |
| Tipo, V | 1 |
| Brenner, SM | 1 |
| Boucher, J | 1 |
| Marchetti, F | 2 |
| Bonati, M | 2 |
| Maestro, A | 2 |
| Zanon, D | 2 |
| Rovere, F | 2 |
| Arrighini, A | 2 |
| Barbi, E | 1 |
| Bertolani, P | 2 |
| Biban, P | 2 |
| Da Dalt, L | 2 |
| Guala, A | 2 |
| Mazzoni, E | 1 |
| Pazzaglia, A | 2 |
| Perri, PF | 1 |
| Reale, A | 2 |
| Renna, S | 2 |
| Urbino, AF | 2 |
| Valletta, E | 2 |
| Vitale, A | 2 |
| Zangardi, T | 2 |
| Clavenna, A | 2 |
| Ronfani, L | 2 |
| Zaremba, J | 1 |
| Wey, AR | 1 |
| Gaillard, PR | 1 |
| Schutz, J | 1 |
| Babl, FE | 1 |
| Sheriff, N | 1 |
| Borland, M | 1 |
| Pfeil, N | 1 |
| Uhlig, U | 1 |
| Kostev, K | 1 |
| Carius, R | 1 |
| Schröder, H | 1 |
| Kiess, W | 1 |
| Uhlig, HH | 1 |
| Alhashimi, D | 4 |
| Al-Hashimi, H | 1 |
| Fedorowicz, Z | 5 |
| Yilmaz, HL | 1 |
| Yildizdas, RD | 1 |
| Sertdemir, Y | 1 |
| Sturm, JJ | 1 |
| Hirsh, DA | 1 |
| Schweickert, A | 1 |
| Massey, R | 1 |
| Simon, HK | 1 |
| Sánchez Etxaniz, J | 1 |
| Paniagua Calzón, N | 1 |
| Gómez Cortés, B | 1 |
| Rumbold, H | 1 |
| Steiner, MJ | 1 |
| Chan, KJ | 2 |
| Howard, S | 1 |
| Nava-Ocampo, AA | 1 |
| Sivabalasundaram, V | 1 |
| Bohn, V | 1 |
| Boutis, K | 1 |
| Di Pietro, P | 1 |
| Mannelli, F | 1 |
| Messi, G | 1 |
| Perri, F | 1 |
| Tondelli, MT | 1 |
| Al-Ansari, K | 1 |
| Alomary, S | 1 |
| Abdulateef, H | 1 |
| Alshawagfa, M | 1 |
| Kamal, K | 1 |
| Jagannath, VA | 1 |
| Carter, B | 1 |
| Tung, C | 1 |
| Cho, D | 1 |
| Rumantir, M | 1 |
| Allan, GM | 1 |
| Wilson, E | 1 |
| Ivers, N | 1 |
| Cayley, WE | 1 |
| Leman, P | 1 |
| Spirko, BA | 1 |
| Hariharan, SL | 1 |
| Pohlgeers, AP | 1 |
| Reeves, SD | 1 |
| Adler, M | 2 |
| Seshadri, R | 2 |
| Alhashimi, H | 3 |
| Gieruszczak-Białek, D | 1 |
| Dylag, M | 1 |
| Mehta, S | 1 |
| Goldman, RD | 1 |
| Freedman, S | 1 |
| Powell, E | 1 |
| Roslund, G | 1 |
| Hepps, TS | 1 |
| McQuillen, KK | 1 |
| Cubeddu, LX | 1 |
| Trujillo, LM | 1 |
| Talmaciu, I | 1 |
| Gonzalez, V | 1 |
| Guariguata, J | 1 |
| Seijas, J | 1 |
| Miller, IA | 1 |
| Paska, W | 1 |
| Ramsook, C | 1 |
| Sahagun-Carreon, I | 1 |
| Kozinetz, CA | 1 |
| Moro-Sutherland, D | 1 |
| Reeves, JJ | 1 |
| Shannon, MW | 1 |
| Fleisher, GR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ondansetron Administration to Children With Gastroenteritis, Vomiting and SOME Dehydration in Emergency Departments in Pakistan[NCT01870648] | Phase 4 | 918 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Randomized, Placebo-Controlled, Phase 3 Trial of BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (The GUARD Study)[NCT02246439] | Phase 3 | 330 participants (Actual) | Interventional | 2014-12-08 | Completed | ||
| Multi-dose Oral Ondansetron For Pediatric Gastroenteritis: A Pragmatic Randomized Controlled Trial[NCT03851835] | Phase 3 | 1,030 participants (Anticipated) | Interventional | 2019-09-04 | Recruiting | ||
| Impact of Emergency Department Probiotic Treatment of Pediatric Gastroenteritis: Randomized Controlled Trial[NCT01853124] | Phase 3 | 886 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis[NCT01773967] | Phase 2/Phase 3 | 971 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| The Effectiveness of Pleuran in Treatment of Acute Gastroenteritis in Children- a Randomized, Placebo-controlled, Double-blind Trial[NCT03988257] | Phase 4 | 27 participants (Actual) | Interventional | 2019-06-24 | Completed | ||
| Emergency Department Rapid Intravenous Rehydration (RIVR) for Pediatric Gastroenteritis: A Randomized Controlled Trial[NCT00392145] | Phase 4 | 226 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Oral Glucose Intervention for Children With Gastroenteritis and Ketosis[NCT02729870] | 0 participants (Actual) | Observational | 2018-01-31 | Withdrawn (stopped due to lack of funding) | |||
| Oral Ondansetron vs Domperidone for Symptomatic Treatment of Vomiting During Acute Gastroenteritis in Children: Multicentre Randomized Controlled Trial[NCT01257672] | Phase 3 | 356 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Ondansetron Vs Metoclopramide in the Treatment of Vomiting in Gastroenteritis Patients: A Randomized Controlled Trial[NCT01165866] | Phase 4 | 170 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting[NCT02473887] | Phase 1 | 40 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Comparison of Efficacy of Ondansetron Versus Metoclopramide for Vomiting in Children With Acute Gastroenteritis: Randomized Controlled Clinical Trial[NCT02619201] | Phase 3 | 250 participants (Anticipated) | Interventional | 2015-11-30 | Not yet recruiting | ||
| Does Oral Propranolol Accelerate Labor Induction/Augmentation With Oxytocin in Nulliparous Women in Abakaliki?[NCT05251610] | 110 participants (Actual) | Interventional | 2020-11-02 | Completed | |||
| Ondansetron vs. Placebo in the Management of Children With Dehydration Due to Acute Gastroenteritis[NCT00691275] | 0 participants (Actual) | Interventional | 2008-09-30 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients receiving parenteral hydration within 24 hours after the first dose of study medication. (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-102 | 34 |
| Placebo Oral Tablet | 32 |
Patients receiving rescue antiemetic therapy within 24 hours after the first dose of study medication. (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-102 | 48 |
| Placebo Oral Tablet | 43 |
Number of patients requiring hospitalization. 4 patients in the RHB-102 treatment group and 1 patient in the placebo treatment group were hospitalized due to lack of efficacy. The remaining patients hospitalized were admitted for reasons other than gastroenteritis. (NCT02246439)
Timeframe: Day 1 of Study - Day 5 of Study
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-102 | 11 |
| Placebo Oral Tablet | 3 |
Proportion of patients returning to emergency department for gastrointestinal symptoms within 4 days of initial discharge (NCT02246439)
Timeframe: Day 1 of Study - Day 5 of Study
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-102 | 4 |
| Placebo Oral Tablet | 4 |
Treatment success, as defined in the primary outcome, through 4 days following first dose of study medication. (NCT02246439)
Timeframe: 4 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-102 | 114 |
| Placebo Oral Tablet | 67 |
Number of patients without further vomiting, without rescue medication, and who were not given intravenous hydration from 30 minutes post first dose until 24 hours post dose (analyzed using logistic regression with treatment as a factor and baseline nausea severity as a continuous variable) (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-102 | 126 |
| Placebo Oral Tablet | 70 |
Number of patients without further vomiting, without rescue medication, and who were not given intravenous hydration from 30 minutes post first dose until 24 hours post dose (analyzed using logistic regression with treatment as a factor and baseline nausea severity as a continuous variable) (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-102 | 123 |
| Placebo Oral Tablet | 67 |
Examination of treatment success rates by age (<18 and ≥18 years). (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| < 18 years of age | 18 years of age or older | |
| Placebo Oral Tablet | 5 | 62 |
| RHB-102 | 11 | 112 |
Severity of nausea was assessed using a 5-point Likert scale: 0=no nausea; 1=mild nausea; 2=moderate nausea; 3=severe nausea; 4=nausea as bad as can be. (NCT02246439)
Timeframe: Day 1 - Baseline through 5 Hours Post Dose
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Hour 1 Post Dose | Hour 2 Post Dose | Hour 3 Post Dose | Hour 4 Post Dose | Hour 5 Post Dose | |
| Placebo Oral Tablet | 2.6 | 1.3 | 0.9 | 0.8 | 0.6 | 0.2 |
| RHB-102 | 2.8 | 1.1 | 0.8 | 0.5 | 0.4 | 0.1 |
Time from first dose of study medication to discharge from ED, extended observation unit or hospital, whichever comes last, and when clinically appropriate. (NCT02246439)
Timeframe: Hours from first dose of study medication to discharge from ED, extended observation unit or hospital, whichever comes last
| Intervention | Hours (Median) | ||
|---|---|---|---|
| All ages | < 18 years of age | 18 years of age or older | |
| Placebo Oral Tablet | 4.3 | 4.8 | 4.2 |
| RHB-102 | 4.3 | 4.3 | 4.3 |
Time from first dose of study medication to resumption of normal activities (work/school/household). (NCT02246439)
Timeframe: Hours from first dose of study medication to resumption of normal activities
| Intervention | Hours (Median) | ||
|---|---|---|---|
| All ages | < 18 years of age | 18 years of age or older | |
| Placebo Oral Tablet | 3 | 4 | 3 |
| RHB-102 | 3 | 2 | 3 |
Number of patients without further vomiting, without rescue medication, and who were not given intravenous hydration from 30 minutes post first dose until 24 hours post dose (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| All ages | <18 years of age | 18 years of age or older | |
| Placebo Oral Tablet | 70 | 5 | 65 |
| RHB-102 | 126 | 12 | 114 |
Proportion of patients without further vomiting, without rescue medication, and who were not given intravenous hydration from 30 minutes post first dose until 24 hours post dose (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| All ages | <18 years of age | 18 years of age or older | |
| Placebo Oral Tablet | 67 | 5 | 62 |
| RHB-102 | 123 | 11 | 112 |
Proportion of patients without further vomiting, without rescue medication, and who were not given intravenous hydration from 30 minutes post first dose until 24 hours post dose (NCT02246439)
Timeframe: 24 Hours
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| No nausea or mild nausea | Moderate nausea | Severe nausea | Nausea as bad as it could have been | |
| Placebo Oral Tablet | 13 | 24 | 22 | 11 |
| RHB-102 | 22 | 26 | 47 | 31 |
diarrhea duration in hours after randomization (NCT01773967)
Timeframe: 14 days
| Intervention | hours (Median) |
|---|---|
| Lactobacillus Rhamnosus GG | 49.7 |
| Placebo | 50.9 |
bacteremia caused by LGG (NCT01773967)
Timeframe: 1 month
| Intervention | Participants (Count of Participants) |
|---|---|
| Lactobacillus Rhamnosus GG | 0 |
| Placebo | 0 |
This is a validated gastroenteritis severity score that includes duration and frequency of diarrhea, duration and frequency of vomiting, duration and frequency of fever and use of health care resources. Scores >=9 indicate moderate-severe gastroenteritis. Higher is worse. (NCT01773967)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Lactobacillus Rhamnosus GG | 55 |
| Placebo | 60 |
19 reviews available for ondansetron and Gastroenteritis
| Article | Year |
|---|---|
Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis.
Topics: Acute Disease; Antiemetics; Child; Child, Preschool; Dexamethasone; Diarrhea; Dimenhydrinate; Domper | 2020 |
Single-dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis-an updated systematic review and meta-analysis.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Drug Administration Schedule; Gastroenteritis; Humans | 2020 |
Effect of ondansetron on vomiting associated with acute gastroenteritis in a developing country: a meta-analysis.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Dehydration; Developing Countries; | 2020 |
Update on nonantibiotic therapies for acute gastroenteritis.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Anti-Bacterial | 2020 |
Outcomes of ondansetron use in children with gastroenteritis in the emergency department: a literature review.
Topics: Antiemetics; Child; Emergency Service, Hospital; Gastroenteritis; Humans; Ondansetron | 2021 |
Clinical Practice: Nausea and vomiting in acute gastroenteritis: physiopathology and management.
Topics: Acute Disease; Antiemetics; Combined Modality Therapy; Fluid Therapy; Gastroenteritis; Humans; Nause | 2018 |
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Fluid Therapy; Gastroenteritis; Hos | 2018 |
Gastroenteritis in Children.
Topics: Adolescent; Antiemetics; Bicarbonates; Child; Child, Preschool; Dehydration; Fluid Therapy; Gastroen | 2019 |
Treatment of acute gastroenteritis in children: an overview of systematic reviews of interventions commonly used in developed countries.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adolescent; Antiemetics; Child; Ch | 2013 |
Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries.
Topics: Acute Disease; Antiemetics; Child; Combined Modality Therapy; Developed Countries; Gastroenteritis; | 2015 |
Ondansetron for gastroenteritis in children and adolescents.
Topics: Adolescent; Antiemetics; Child; Diarrhea; Gastroenteritis; Humans; Ondansetron; Vomiting | 2015 |
Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Antiemetics; Child; Child, Prescho | 2016 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Gastroenteritis; Humans; Metoclopra | 2009 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Bet 2. Ondansetron in childhood gastroenteritis.
Topics: Administration, Oral; Child, Preschool; Evidence-Based Medicine; Gastroenteritis; Gastrointestinal A | 2010 |
Archimedes. Question 1. Does oral ondansetron reduce vomiting and the need for intravenous fluids and hospital admission in children presenting with vomiting secondary to gastroenteritis?
Topics: Administration, Oral; Antiemetics; Child, Preschool; Evidence-Based Medicine; Female; Gastroenteriti | 2010 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Fluid Therapy; Gastroenteritis; Hos | 2011 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Gastroenteritis; Humans; Metoclopramide; Ondansetron; | 2006 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Gastroenteritis; Humans; Metoclopramide; Ondansetron; | 2006 |
Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children.
Topics: Antiemetics; Child; Child, Preschool; Gastroenteritis; Humans; Infant; Ondansetron; Randomized Contr | 2007 |
19 trials available for ondansetron and Gastroenteritis
| Article | Year |
|---|---|
Oral Ondansetron Administration to Dehydrated Children in Pakistan: A Randomized Clinical Trial.
Topics: Administration, Oral; Antiemetics; Child, Preschool; Dehydration; Double-Blind Method; Emergency Ser | 2019 |
Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Double-Blind Method; Female; Gastroenteritis; | 2019 |
Absence of QT prolongation after administration of a 24-mg bimodal-release ondansetron pill (RHB-102).
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Delayed-Action Preparations; Double-Blind Meth | 2021 |
Multi-dose Oral Ondansetron for Pediatric Gastroenteritis: study Protocol for the multi-DOSE oral ondansetron for pediatric Acute GastroEnteritis (DOSE-AGE) pragmatic randomized controlled trial.
Topics: Administration, Oral; Antiemetics; Canada; Child; Clinical Trials, Phase III as Topic; Cost-Benefit | 2020 |
A pragmatic randomized controlled trial of multi-dose oral ondansetron for pediatric gastroenteritis (the DOSE-AGE study): statistical analysis plan.
Topics: Administration, Oral; Antiemetics; Child; Clinical Trials, Phase III as Topic; Fluid Therapy; Gastro | 2020 |
Cost-effectiveness of oral ondansetron for children with acute gastroenteritis in primary care: a randomised controlled trial.
Topics: Administration, Oral; Antiemetics; Child; Cost-Benefit Analysis; Gastroenteritis; Humans; Ondansetro | 2021 |
Oral ondansetron for paediatric gastroenteritis in primary care: a randomised controlled trial.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Double-Blind Method; Gastroenteritis; Hu | 2021 |
Single-dose Intravenous Ondansetron in Children with Gastroenteritis: A Randomized Controlled Trial.
Topics: Antiemetics; Child, Preschool; Dehydration; Diarrhea; Double-Blind Method; Drug Administration Sched | 2019 |
Successful discharge of children with gastroenteritis requiring intravenous rehydration.
Topics: Administration, Intravenous; Antiemetics; Bicarbonates; Biomarkers; Child; Child, Preschool; Dehydra | 2014 |
Oral Ondansetron versus Domperidone for Acute Gastroenteritis in Pediatric Emergency Departments: Multicenter Double Blind Randomized Controlled Trial.
Topics: Acute Disease; Administration, Oral; Antiemetics; Child; Child, Preschool; Domperidone; Double-Blind | 2016 |
Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study.
Topics: Administration, Oral; Child, Preschool; Double-Blind Method; Female; Fluid Therapy; Gastroenteritis; | 2010 |
Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study.
Topics: Child; Child, Preschool; Cohort Studies; Dehydration; Diarrhea; Dose-Response Relationship, Drug; Fe | 2010 |
Oral ondansetron versus domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial.
Topics: Acute Disease; Administration, Oral; Antiemetics; Child; Child, Preschool; Clinical Protocols; Dompe | 2011 |
Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dopamine Antagonists; Double-Blind Method; Female; | 2011 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
Oral ondansetron for gastroenteritis in a pediatric emergency department.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dehydration; Double-Blind Method; Female | 2006 |
The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial.
Topics: Acute Disease; Administration, Oral; Antiemetics; Chi-Square Distribution; Child; Child, Preschool; | 2008 |
Antiemetic activity of ondansetron in acute gastroenteritis.
Topics: Acute Disease; Antiemetics; Child; Child, Preschool; Diarrhea; Female; Fluid Therapy; Gastroenteriti | 1997 |
A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis.
Topics: Acute Disease; Administration, Oral; Child; Child, Preschool; Diarrhea; Double-Blind Method; Female; | 2002 |
Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial.
Topics: Acute Disease; Adolescent; Adult; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; | 2002 |
41 other studies available for ondansetron and Gastroenteritis
| Article | Year |
|---|---|
Managing paediatric gastroenteritis in primary care: is there a role for ondansetron?
Topics: Acute Disease; Child; Gastroenteritis; Humans; Ondansetron; Primary Health Care; Vomiting | 2021 |
The effect of oral ondansetron on QT interval in children with acute gastroenteritis; a retrospective observational study.
Topics: Antiemetics; Child; Child, Preschool; Electrocardiography; Gastroenteritis; Humans; Infant; Long QT | 2021 |
It's Too Soon to Throw Away Oral Ondansetron for Pediatric Gastroenteritis.
Topics: Antiemetics; Child; Gastroenteritis; Humans; Ondansetron | 2022 |
Improving ondansetron use and oral rehydration instructions for pediatric acute gastroenteritis.
Topics: Administration, Oral; Antiemetics; Child; Fluid Therapy; Gastroenteritis; Humans; Ondansetron; Pedia | 2022 |
Racial and Ethnic Differences in Ondansetron Use for Acute Gastroenteritis in Children.
Topics: Child; Ethnicity; Gastroenteritis; Hispanic or Latino; Humans; Ondansetron; Retrospective Studies | 2022 |
[No place for ondansetron in young children with gastroenteritis and persistent vomiting].
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Diarrhea; Double-Blind Method; Drug-Rela | 2022 |
Impact of Ondansetron Prescription on Return Emergency Department Visits Among Children with Acute Gastroenteritis.
Topics: Antiemetics; Child; Cohort Studies; Emergency Service, Hospital; Gastroenteritis; Humans; Ondansetro | 2021 |
Intravenous Ondansetron to Reduce Intravenous Rehydration - Will it be Successful?
Topics: Antiemetics; Child; Fluid Therapy; Gastroenteritis; Humans; Ondansetron | 2019 |
Intravenous Ondansetron to Reduce Intravenous Rehydration - Will it be Successful?: Author's Reply.
Topics: Antiemetics; Child; Fluid Therapy; Gastroenteritis; Humans; Ondansetron | 2019 |
Ondansetron Prescription Is Associated With Reduced Return Visits to the Pediatric Emergency Department for Children With Gastroenteritis.
Topics: Antiemetics; Child; Child, Preschool; Emergency Service, Hospital; Female; Gastroenteritis; Hospital | 2020 |
Variables Associated With Intravenous Rehydration and Hospitalization in Children With Acute Gastroenteritis: A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Administration, Intravenous; Administration, Oral; Antiemetics; Canada; Child, Preschool; Dehydratio | 2021 |
Variables Associated With Intravenous Rehydration and Hospitalization in Children With Acute Gastroenteritis: A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Administration, Intravenous; Administration, Oral; Antiemetics; Canada; Child, Preschool; Dehydratio | 2021 |
Variables Associated With Intravenous Rehydration and Hospitalization in Children With Acute Gastroenteritis: A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Administration, Intravenous; Administration, Oral; Antiemetics; Canada; Child, Preschool; Dehydratio | 2021 |
Variables Associated With Intravenous Rehydration and Hospitalization in Children With Acute Gastroenteritis: A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Administration, Intravenous; Administration, Oral; Antiemetics; Canada; Child, Preschool; Dehydratio | 2021 |
Gastroenteritis Care in the US and Canada: Can Comparative Analysis Improve Resource Use?
Topics: Canada; Gastroenteritis; Humans; Ondansetron | 2021 |
Oral Ondansetron Administration in Children Seeking Emergency Department Care for Acute Gastroenteritis: A Patient-Level Propensity-Matched Analysis.
Topics: Acute Disease; Administration, Oral; Antiemetics; Child, Preschool; Diarrhea; Emergency Service, Hos | 2022 |
Clinical Pathway Produces Sustained Improvement in Acute Gastroenteritis Care.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Combined Modality Therapy; Critical | 2017 |
Effect of intravenous ondansetron on QTc interval in children with gastroenteritis.
Topics: Administration, Intravenous; Adolescent; Antiemetics; Child; Child, Preschool; Electrocardiography; | 2018 |
Ondansetron Prescription for Home Use in a Pediatric Emergency Department.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Electronic Health Records; Emergency Service, Hosp | 2020 |
The addition of ondansetron to a oral rehydration protocol for children with acute gastroenteritis.
Topics: Acute Disease; Antiemetics; Child, Preschool; Emergency Service, Hospital; Female; Fluid Therapy; Ga | 2013 |
Ondansetron for acute gastroenteritis: a failure of knowledge translation.
Topics: Antiemetics; Emergency Service, Hospital; Female; Fluid Therapy; Gastroenteritis; Humans; Male; Onda | 2014 |
Impact of increasing ondansetron use on clinical outcomes in children with gastroenteritis.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Cohort Studies; Emergency Service, Hospital; Femal | 2014 |
Pediatric gastroenteritis in the emergency department: practice evaluation in Belgium, France, The Netherlands and Switzerland.
Topics: Abdomen; Antidiarrheals; Antiemetics; Belgium; Blood Cell Count; Blood Gas Analysis; C-Reactive Prot | 2014 |
Is Ondansetron any use in gastroenteritis?
Topics: Antiemetics; Gastroenteritis; Humans; Ondansetron; Vomiting | 2015 |
Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting in Children.
Topics: Administration, Intravenous; Administration, Oral; Antiemetics; Child; Child, Preschool; Female; Gas | 2016 |
Ondansetron Oral Dissolve Tab vs. Oral Solution in Children Presenting to the Emergency Department with Gastroenteritis.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Emergency Service, Hospital; Female; Flu | 2016 |
Ondansetron as the first approach in the management of the patients with acute gastroenteritis visiting the pediatric emergency department: A single-center experience.
Topics: Acute Disease; Antiemetics; Child, Preschool; Emergency Service, Hospital; Female; Gastroenteritis; | 2016 |
Fatal Cardiac Arrest in 2 Children: Possible Role of Ondansetron.
Topics: Child; Fatal Outcome; Gastroenteritis; Heart Arrest; Humans; Infant; Male; Ondansetron; United State | 2016 |
The Use of a Triage-Based Protocol for Oral Rehydration in a Pediatric Emergency Department.
Topics: Antiemetics; Child, Preschool; Critical Pathways; Dehydration; Emergency Service, Hospital; Female; | 2018 |
Emergency department management of gastro-enteritis in Australia and New Zealand.
Topics: Acute Disease; Antiemetics; Australia; Data Collection; Dehydration; Diarrhea; Emergency Medicine; E | 2008 |
Antiemetic medications in children with presumed infectious gastroenteritis--pharmacoepidemiology in Europe and Northern America.
Topics: Antiemetics; Child; Child, Preschool; Dimenhydrinate; Diphenhydramine; Domperidone; Europe; Female; | 2008 |
Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses?
Topics: Abdominal Pain; Adolescent; Antiemetics; Child; Child, Preschool; Confidence Intervals; Cross-Sectio | 2010 |
[Ondansetron use in paediatric emergencies].
Topics: Acute Disease; Antiemetics; Child; Dose-Response Relationship, Drug; Gastroenteritis; Humans; Intens | 2010 |
Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis.
Topics: Administration, Oral; Algorithms; Antiemetics; Canada; Child; Child, Preschool; Cost-Benefit Analysi | 2010 |
The treatment of pediatric gastroenteritis: a comparative analysis of pediatric emergency physicians' practice patterns.
Topics: Adolescent; Antiemetics; Canada; Child; Child, Preschool; Cross-Sectional Studies; Emergency Medicin | 2011 |
Time-series analysis of ondansetron use in pediatric gastroenteritis.
Topics: Antiemetics; Canada; Child; Child, Preschool; Dehydration; Female; Fluid Therapy; Gastroenteritis; H | 2012 |
Can ondansetron help children with vomiting due to gastroenteritis?
Topics: Antiemetics; Child; Child, Preschool; Gastroenteritis; Humans; Infant; Ondansetron; Treatment Outcom | 2012 |
Antiemetics for acute gastroenteritis-related vomiting in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Dimenhydrinate; Gastroenteritis; Humans; Metocloprami | 2012 |
Utility of ondansetron in children with vomiting.
Topics: Antiemetics; Child; Emergency Service, Hospital; Gastroenteritis; Humans; Ondansetron; Severity of I | 2002 |
Antiemetic use for gastroenteritis in children.
Topics: Acute Disease; Administration, Oral; Age Factors; Antiemetics; Child; Diarrhea; Emergency Treatment; | 2003 |
"Doctor, my child needs some medicine!".
Topics: Abdominal Pain; Adolescent; Analgesics; Anti-Bacterial Agents; Antiemetics; Child, Preschool; Dehydr | 2004 |
Ondansetron for acute gastroenteritis in children.
Topics: Acute Disease; Antiemetics; Child; Dehydration; Diarrhea; Fluid Therapy; Gastroenteritis; Humans; On | 2006 |
Re: selected summary of "antiemetics for acute gastroenteritis: a never ending story".
Topics: Acute Disease; Antiemetics; Fluid Therapy; Gastroenteritis; Humans; Ondansetron; Vomiting | 2007 |
Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children.
Topics: Antiemetics; Child; Gastroenteritis; Humans; Ondansetron; Vomiting | 2007 |